FDA approves Merus’ Bizengri as the first treatment for advanced NRG1 fusion-positive cancers. U.S. peak sales are estimated at $16.5 million. Latest Ratings for MRUS Date Firm Action From To Feb 2022 BMO Capital Initiates Coverage On Outperform Feb 2022 Needham Initiates Coverage On Buy Nov 2021 HC Wainwright & Co. Maintains Buy View More…
Latest Ratings for DOV Date Firm Action From To Jan 2022 Morgan Stanley Maintains Equal-Weight Jan 2022 Morgan Stanley Maintains Equal-Weight Jan 2022 Oppenheimer Upgrades Perform Outperform View More Analyst Ratings for DOV View the Latest Analyst Ratings read more
Latest Ratings for CFLT Date Firm Action From To Feb 2022 Deutsche Bank Maintains Hold Feb 2022 Credit Suisse Maintains Outperform Feb 2022 Morgan Stanley Maintains Equal-Weight View More Analyst Ratings for CFLT View the Latest Analyst Ratings read more
Latest Ratings for DUOL Date Firm Action From To Mar 2022 Evercore ISI Group Maintains Outperform Mar 2022 Piper Sandler Maintains Overweight Jan 2022 Piper Sandler Maintains Overweight View More Analyst Ratings for DUOL View the Latest Analyst Ratings read more
Latest Ratings for TPB Date Firm Action From To Oct 2020 Barclays Initiates Coverage On Overweight Jul 2020 Craig-Hallum Initiates Coverage On Buy Nov 2019 Buckingham Research Initiates Coverage On Buy View More Analyst Ratings for TPB View the Latest Analyst Ratings read more
Latest Ratings for MRVI Date Firm Action From To Feb 2022 Morgan Stanley Maintains Overweight Aug 2021 Morgan Stanley Maintains Overweight Aug 2021 Credit Suisse Maintains Outperform View More Analyst Ratings for MRVI View the Latest Analyst Ratings read more
Latest Ratings for DV Date Firm Action From To Mar 2022 Canaccord Genuity Maintains Buy Mar 2022 RBC Capital Maintains Outperform Mar 2022 Barclays Maintains Equal-Weight View More Analyst Ratings for DV View the Latest Analyst Ratings read more